The clinical stakes are considerable. In children, hypercalcemia can present anywhere along a spectrum from an incidental laboratory finding to vomiting, dehydration, lethargy, hypertension, arrhythmia, acute kidney injury, nephrocalcinosis, or failure to thrive. While primary hyperparathyroidism and malignancy dominate the adult landscape, the causes in neonates, infants, and toddlers skew differently: nutritional excess, vitamin D metabolic disorders, renal phosphate-handling defects, calcium-sensing pathway disorders, subcutaneous fat necrosis, and syndromic disease all demand earlier consideration. The editorial is explicitly framed as an expert-informed triage aid rather than a formal guideline, and its authors stress that outcome-validated studies are still needed.

The framework’s first decision point is deceptively basic: is this really hypercalcemia, and how severe is it? Confirmation and severity assessment should proceed in parallel with stabilization. Total calcium must be interpreted alongside serum albumin, and corrected or ionized calcium may be needed—particularly when albumin is abnormal, acid–base disturbance is present, or the child is critically ill. The authors emphasize that pediatric calcium reference intervals are age-dependent, and that adult-derived ranges may misclassify infants and young children. As practical severity prompts, albumin-adjusted total calcium above 10.5 mg/dL (2.60 mmol/L) or ionized calcium above 5.25 mg/dL (1.32 mmol/L) supports true hypercalcemia, while values approaching or exceeding 12–14 mg/dL (3.00–3.50 mmol/L), rapidly rising calcium, or hypercalcemia accompanied by dehydration, altered mental status, arrhythmia, severe vomiting, renal dysfunction, or nephrocalcinosis should trigger immediate supportive care while the diagnostic workup continues.

That initial evaluation should include serum albumin, iPTH, phosphate, magnesium, alkaline phosphatase, creatinine, 25-hydroxyvitamin D, and a spot urinary calcium-to-creatinine ratio (UCa/UCr). During acute management, calcium, phosphate, magnesium, creatinine, fluid balance, urine output, and clinical status should be reassessed serially, with electrocardiographic monitoring when hypercalcemia is moderate to severe or when symptoms, arrhythmia, renal dysfunction, or relevant electrolyte abnormalities are present. A focused history matters too: calcium or exogenous vitamin D exposure, formula preparation, parenteral nutrition, medications, immobilization, malignancy, renal or transplant history, and family history can all reshape the differential. Renal ultrasonography is useful when hypercalcemia persists, hypercalciuria or renal impairment is present, nephrolithiasis or nephrocalcinosis is suspected, or onset is in infancy.

On the treatment side, isotonic saline is usually first-line for significant or symptomatic hypercalcemia, restoring intravascular volume and promoting renal calcium excretion—though fluid overload must be watched in children with renal or cardiac disease. Notably, the authors caution against routine loop diuretics; if used, they should follow volume restoration and close electrolyte monitoring, and are mainly reserved for fluid overload after euvolemia is achieved. Calcitonin acts rapidly but briefly; glucocorticoids are most useful for vitamin D-mediated or granulomatous disease; and bisphosphonates offer more sustained effects but carry risks of delayed onset, hypocalcemia, renal toxicity, and prolonged skeletal retention in children. In potentially transient infantile conditions such as subcutaneous fat necrosis, bisphosphonates should generally be reserved for severe, prolonged, or persistent hypercalcemia refractory to aggressive hydration and calcitonin. Dialysis remains a last resort for life-threatening or refractory cases, particularly with renal failure or fluid intolerance. Importantly, the authors note that improvement after hydration does not establish dehydration as the underlying cause.

The framework’s central biochemical hinge is iPTH, and the authors deliver a memorable warning: in true hypercalcemia, parathyroid hormone should be suppressed, so a value reported as “normal” may actually be inappropriate if calcium is elevated. Suppressed iPTH points toward iPTH-independent hypercalcemia—vitamin D intoxication or impaired vitamin D catabolism, malignancy, granulomatous disease, immobilization, subcutaneous fat necrosis, medication-related causes, and selected genetic or syndromic disorders. A non-suppressed, inappropriately normal, or elevated iPTH raises concern for iPTH-dependent disease, including primary hyperparathyroidism, familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, multiple endocrine neoplasia-related disease, and tertiary hyperparathyroidism. If the phenotype and iPTH result are discordant, repeat testing after stabilization is reasonable, since biotin exposure, assay differences, renal dysfunction, and sampling after treatment can all complicate interpretation.

Age then becomes the lens through which iPTH-independent causes are prioritized. In neonates, infants, and young toddlers, clinicians should first revisit intake and exposure, because excess vitamin D or calcium is reversible and easily missed. If exposure does not explain the picture, inherited or syndromic disease should be considered early—especially when hypercalcemia is persistent, recurrent, or accompanied by hypercalciuria, hypophosphatemia, nephrocalcinosis, or a positive family history. CYP24A1- and SLC34A1-related disease and Williams–Beuren syndrome are highlighted as important examples. A subtle technical point carries real weight here: a normal 25-hydroxyvitamin D level does not exclude impaired vitamin D catabolism, and 1,25-dihydroxyvitamin D results may not be available when early inpatient decisions must be made. Once available, elevated or inappropriately normal 1,25-dihydroxyvitamin D despite suppressed iPTH supports vitamin D-mediated hypercalcemia and may point toward impaired catabolism, renal phosphate-handling defects, or extrarenal 1α-hydroxylase activity.

In older children and adolescents with suppressed iPTH, acquired causes move to the fore: malignancy, immobilization, iatrogenic or drug-induced hypercalcemia, granulomatous infection or inflammation, vitamin A excess, thiazides, and endocrine disorders including thyrotoxicosis and adrenal insufficiency. In children with chronic kidney disease or after transplantation, the iPTH pattern and treatment exposure should guide classification, because treatment-related hypercalcemia may be iPTH independent while persistent or tertiary hyperparathyroidism is iPTH dependent. Parathyroid hormone-related peptide testing may help when malignancy is suspected, though assay and age-related interpretation require caution.

The third pillar—urinary calcium—exists to prevent one of the most consequential errors in this field: misclassifying familial hypocalciuric hypercalcemia (FHH) as primary hyperparathyroidism. FHH is usually mild, lifelong, and often familial, and parathyroidectomy is usually ineffective. Relative hypocalciuria for age and context should therefore prompt family calcium testing and consideration of CASR, GNA11, and AP2S1 genetic testing before localization imaging or surgery. The authors stress that urinary calcium indices are supportive, not diagnostic, and that a spot urine sample for UCa/UCr should be collected within the same clinical time frame as serum calcium and iPTH whenever feasible—asynchronous sampling during hydration, diuretic use, or rapid calcium fluctuation can mislead. Infants normally have higher UCa/UCr than older children, and hydration, sodium intake, renal function, diuretics, and vitamin D status all alter results. Conversely, primary hyperparathyroidism can sometimes appear relatively hypocalciuric, especially with renal dysfunction, low calcium intake, vitamin D deficiency, or thiazide exposure. In neonates with severe hypercalcemia and non-suppressed iPTH, neonatal severe hyperparathyroidism or CASR-related disease should be considered urgently.

Finally, the framework calls for earlier but selective genetic testing. Not every transient mild episode warrants sequencing, but infantile onset, persistent or recurrent hypercalcemia, nephrocalcinosis or nephrolithiasis, family history, syndromic features, or discordant results after common causes are excluded should all accelerate testing. Infantile hypercalcemia with suppressed iPTH supports a panel or exome strategy including vitamin D metabolism and renal phosphate-handling genes such as CYP24A1 and SLC34A1, while non-suppressed iPTH with relative hypocalciuria supports calcium-sensing pathway testing. Dysmorphism, congenital heart disease, developmental delay, or multisystem involvement may require chromosomal microarray or syndrome-directed testing, and early-onset primary hyperparathyroidism, multigland disease, recurrence, parathyroid carcinoma, jaw tumor features, or family history should raise concern for MEN1-, CDC73-, RET-, or CDKN1B-related disease. Variants of uncertain significance, the authors caution, should not be treated as diagnostic without biochemical and segregation support. Because pediatric inpatient hypercalcemia is uncommon, the authors frame their proposal as a starting point, calling for multicenter studies or registry-based audits to test whether structured use of iPTH, age, and urinary calcium genuinely improves diagnostic timeliness, treatment escalation, renal outcomes, avoidance of inappropriate surgery, and hospital stay.

Subject of Research: Triage of pediatric inpatient hypercalcemia using intact parathyroid hormone, age, and urinary calcium

Article Title: Pediatric inpatient hypercalcemia: triage using intact parathyroid hormone, age, and urinary calcium

Article References: Lin, H., Fu, J.-F., & Dong, G.-P. (2026). Pediatric inpatient hypercalcemia: triage using intact parathyroid hormone, age, and urinary calcium. World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01102-w

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01102-w

Keywords: hypercalcemia, pediatrics, parathyroid hormone, urinary calcium, familial hypocalciuric hypercalcemia, CYP24A1, SLC34A1, vitamin D metabolism, neonatal severe hyperparathyroidism, genetic testing, calcium-sensing pathway, World Journal of Pediatrics